Cigna (CI) Reports Q4 Earnings: What Key Metrics Have to Say

Core Insights - Cigna reported $65.68 billion in revenue for Q4 2024, a year-over-year increase of 28.4%, exceeding the Zacks Consensus Estimate by 3.85% [1] - The EPS for the quarter was $6.64, which is a decrease of 2.2% from $6.79 a year ago, falling short of the consensus estimate of $7.83 by 15.20% [1] Financial Performance Metrics - Medical Care Ratio was reported at 87.9%, higher than the estimated 84.5% [4] - Total Medical Customers reached 19.15 million, slightly below the average estimate of 19.17 million [4] - Revenues from Fees and Other amounted to $3.93 billion, surpassing the estimate of $3.73 billion, reflecting a year-over-year increase of 29% [4] - Premium revenues were $11.50 billion, exceeding the estimate of $11.45 billion, with a year-over-year growth of 2.9% [4] - Pharmacy revenues reached $49.94 billion, significantly above the estimate of $48.20 billion, marking a 36.4% year-over-year increase [4] - Revenues from Evernorth Health Services were $53.74 billion, compared to the estimate of $51.10 billion, representing a year-over-year change of 32.6% [4] - Cigna Healthcare Premium revenues were $11.38 billion, exceeding the estimate of $11.27 billion, with a year-over-year increase of 2.5% [4] - Net investment income was reported at $277 million, above the estimate of $254.43 million, but down 4.5% from the previous year [4] - Cigna Healthcare revenues were $13.30 billion, slightly below the estimate of $13.37 billion, reflecting a year-over-year increase of 2.5% [4] - Evernorth Health Services Pharmacy revenues were $50.75 billion, exceeding the estimate of $48.74 billion, with a year-over-year increase of 34.4% [4] Stock Performance - Cigna's shares have returned +9.8% over the past month, outperforming the Zacks S&P 500 composite's +1.2% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]